ACIP Mtg Update PCV Vaccine Recommendations Adults

Important Update:  The recommended age for adult pneumococcal vaccination has been lowered to 50 years. Both Pfizer's Prevnar 20® (PCV 20) and Merck's Capvaxive®(PCV 21) are approved & now recommended for this PCV naïve adults 50 years of age and older.

· PCV21 should not be viewed simply as PCV20 plus one additional serotype. Data show that PCV21 covers an additional ~23% of IPD serotypes in 19-64 year olds and an additional ~31% of IPD serotypes in those ≥65 years

· ACIP voted to recommend a pneumococcal conjugate vaccine (PCV) for all PCV-naïve adults aged ≥50 years. 14 members voted in favor only 1 voted against.

· Important: the ACIP Pneumococcal WG will re-evaluate the potential recommendation for a 2nd dose in the future to avoid shifting the burden of disease to older adults with the lower age-based recommendation

 Watch the ACIP meeting recording here.

References

1.  ACIP Presentation. Loehr J. 23 October 2024. Pneumococcal Vaccines. (LINK)

2.  ACIP Presentation. Stoecker C. 23 October 2024. Economic Analysis and Public Health Impact of PCV use for Adults Aged ≥50 Years. (LINK)

3.  ACIP Presentation. Leidner A. 23 October 2024. Summary of three economic analyses on the use of PCVs among 50-64 year old adults in the United States (LINK)

4. ACIP Presentation. Kobayashi M. 23 October 2024. Summary of Work Group Interpretation of EtR and Policy Options PCV Use in Adults aged ≥50 years (LINK)